Eptifibatide
| Evidence Level: L3 | Predicted Indications: 10 |
Table of Contents
Eptifibatide: From Acute Coronary Syndrome to Hemoglobinopathy (Sickle Cell Disease)
One-Sentence Summary
Eptifibatide is a GPIIb/IIIa (αIIbβ3 integrin) antagonist historically used to inhibit platelet aggregation in acute coronary syndromes. Among the 10 TxGNN-predicted indications for this drug, Hemoglobinopathy (sickle cell disease vaso-occlusive crisis) is the only candidate with real human trial data — 1 completed-phase clinical trial (terminated) and 4 supporting publications — even though it ranks 7th, not 1st, by raw TxGNN score. The top-ranked prediction (rheumatoid arthritis, score 99.99%) has zero supporting evidence and is therefore not the focus of this report.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Acute Coronary Syndrome (ACS) / Unstable Angina — inferred from cited literature context; no formal regulatory label text is available since this product is not marketed in this jurisdiction |
| Predicted New Indication | Hemoglobinopathy (sickle cell disease, acute vaso-occlusive pain crisis) |
| TxGNN Prediction Score | 99.98% (rank #441 overall) |
| Evidence Level | L3 |
| EU Market Status | Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Eptifibatide is a cyclic heptapeptide GPIIb/IIIa (integrin αIIbβ3) receptor antagonist that blocks the final common pathway of platelet aggregation. This mechanism underlies its established antithrombotic use in acute coronary syndromes, where blocking fibrinogen cross-linking between platelets prevents thrombus propagation in the coronary vasculature (as referenced in the cited literature).
Sickle cell disease and related hemoglobinopathies share a pathophysiology in which platelet activation and adhesion contribute to microvascular occlusion, driving the acute painful crises that define the disease. Because Eptifibatide’s core action — blocking platelet aggregation via αIIbβ3 — is mechanistically agnostic to the vascular bed involved, a link between Eptifibatide and hemoglobinopathy is biologically plausible. This is also the only candidate among this drug’s top 10 TxGNN predictions that has already been tested directly in humans: a Phase I/II trial (NCT00834899) plus three independent publications from the same U.S. research group examining safety, pain-crisis outcomes, and inflammatory markers.
By comparison, the other high-scoring TxGNN candidates (rheumatoid arthritis, several sickle-cell subtype syndromes without independent data, beta-thalassemia, and the 16p13 deletion syndrome) rest mainly on ontological proximity within the knowledge graph rather than independent evidence, and should be treated as far more speculative. A separate, low-tier signal also exists for female breast carcinoma, based only on in vitro/microfluidic-chip data showing αIIbβ3 blockade may reduce platelet-tumor cell interactions relevant to metastasis — this is preclinical only and not pursued further here.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT00834899 | Phase 1/2 | Terminated | 13 | Evaluated safety and efficacy of Eptifibatide for acute pain episodes in sickle cell disease, testing the hypothesis that platelet activation and resultant inflammation contribute to vaso-occlusive crises. Terminated early (2012); reason not stated in available data. |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 17916103 | 2007 | Phase 1 Clinical Trial | British Journal of Haematology | First-in-SCA-patient study; Eptifibatide safely inhibited platelet aggregation and CD40 ligand release in 4 steady-state sickle cell anaemia patients, supporting the ACS-like platelet/CD40L pathophysiology rationale. |
| 23973010 | 2013 | Pilot Clinical Study | Thrombosis Research | Pilot study of Eptifibatide during acute painful episodes in SCD; evaluated safety and efficacy of αIIbβ3 blockade in reducing crisis-related platelet activation. |
| 29322543 | 2018 | Clinical Study (Post-hoc/Mechanistic) | American Journal of Hematology | Follow-up analysis from the same trial cohort examining Eptifibatide’s effect on inflammatory markers during acute pain episodes. |
| 22156199 | 2012 | In Vitro Preclinical | The Journal of Clinical Investigation | Microfluidic “endothelialized” model of microvascular occlusion/thrombosis in hematologic diseases (SCD, HUS); supports the general biophysical mechanism but does not test Eptifibatide directly. |
Safety Considerations
Please refer to the SmPC for safety information. No drug-drug interaction records, key warnings, or contraindication data were found for this drug in the current evidence pack.
Conclusion and Next Steps
Decision: Hold
Rationale: The mechanistic rationale is sound and this is the only one of Eptifibatide’s 10 TxGNN-predicted indications with direct human trial data, but the pivotal trial (NCT00834899, n=13) was terminated for an undocumented reason and no properly powered efficacy trial exists. This is insufficient to move beyond a research hypothesis at this time.
To proceed, the following is needed:
- Reason for termination of NCT00834899 (safety, futility, or enrollment failure changes the risk calculus materially)
- Official mechanism-of-action and labeling/safety data (SmPC/TFDA-equivalent warnings and contraindications — currently a blocking data gap)
- A properly powered Phase 2 trial with vaso-occlusive crisis frequency/duration as a primary endpoint
- Bleeding-risk assessment specific to the SCD population, given baseline coagulopathy differences from the ACS population where Eptifibatide is conventionally used
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.